Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(16 sites) United States
California Research Institute, Los Angeles, California BRCR Global, Tamarac, Florida Gabrail Cancer Center Research, Canton, Ohio Ohio State University, Columbus, Ohio Allegheny Health Network, Pittsburgh, Pennsylvania UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania University of Texas Southwestern Medical Center, Dallas, Texas MD Anderson Cancer Center, Houston, Texas Virginia Cancer Specialists, PC, Fairfax, Virginia Australia
St Vincent's Hospital, Darlinghurst, New South Wales Cancer Care Wollongong, Wollongong, New South Wales University of the Sunshine Coast Clinical Trials, Buderim, Queensland Tasman Oncology Research, Southport, Queensland Princess Alexandra Hospital | Metro South Health, Woolloongabba, Queensland Southern Oncology Clinical Research Unit, Bedford Park, South Australia St John of God Subiaco Hospital, Subiaco, Western Australia